論文・技術情報追加のお知らせ

1. Ocular toxicity associated with anti-HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database.

抗HER2薬の眼毒性リスクをFAERSで調査

対象DB：FAERS

2. Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database.

セクキニュマブ使用に関連する有害事象をFAERSから調査

対象DB：FAERS

3. A Real-World Data Derived Pharmacovigilance Assessment on Drug-Induced Nephropathy: Implication on Gaps in Patient Care.

KAERSにおける薬剤誘発性腎毒性の有病率と重篤性を調査

対象DB：FAERS,KAERS

4. Medication Associations with Severe Cutaneous Adverse Reactions: A Case/Non-Case Analysis Using the FDA Adverse Event Reporting System.

FAERSを用いて、SJS、TEN、DRESS、AGEPといった重篤な皮膚副作用を引き起こす可能性のある薬物を調査

対象DB：FAERS

5. Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.

FAERSを用いてQT延長およびTdPに関連する報告をレビュー

対象DB：FAERS

6. A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database.

FAERSを用いてメポリズマブの副作用を評価

対象DB：FAERS

7. Disproportionality analysis of stomatitis associated with anticancer drugs using Japanese Adverse Drug Event Reporting Database.

JADERを用いて、さまざまながん患者において抗がん剤と口内炎の関連を検討

対象DB：JADER

8. Leveraging COVID-19 Vaccine Safety Monitoring in Ethiopia and Pakistan to Enhance System-Wide Safety Surveillance.

エチオピアとパキスタンでは、COVID-19ワクチンの副反応モニタリングのため、薬剤監視システムの報告数および因果関係の評価が向上

対象DB：VigiBase

9. Autoimmune disorders reported following COVID-19 vaccination: A disproportionality analysis using the WHO database.

COVID-19ワクチン接種後の自己免疫障害に関連した16の有害事象の潜在的な安全性シグナルをVigiBaseで評価

対象DB：VigiBase

10. Safety of COVID-19 Vaccination During Pregnancy and Lactation: A VigiBase Analysis.

COVID-19ワクチン接種と妊娠・授乳の関連の検討

対象DB：VigiBase

11. Evaluation of hospital pharmacists' activities using additional reimbursement for infection prevention as an indicator in small and medium-sized hospitals.

日本の病院で追加報酬を受けるための感染症予防活動（ARIP）が導入され、100～299床の病院の薬剤師の活動を調査

対象DB：DPC

12. Treatment patterns and drug survival for generalized pustular psoriasis: A patient journey study using a Japanese claims database.

日本での全身性膿疱性乾癬の実態調査

対象DB：MDV

13. Persons diagnosed with COVID-19 in England in the Clinical Practice Research Datalink (CPRD): a cohort description.

CPRD Aurumを用い、COVID-19の確定診断、ワクチン接種状況、高リスクの3つの定義を作成

対象DB：CPRD

14. Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and/or type 2 diabetes: a longitudinal cohort study.

FIB-4指数と肝疾患、心血管イベント、全死因死亡の関連を検討

対象DB：CPRD

15. Clostridioides difficile infections, recurrences, and clinical outcomes in real-world settings from 2015-2019: The RECUR England study.

英国におけるクロストリジオイデス・ディフィシル感染、再発の疫学的および臨床的負担を評価

対象DB：CPRD

16. Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

ランダム化、二重盲検、プラセボ対照の第3相試験で、リナクロチドの小児機能性便秘への効果と安全性が評価

対象DB：CVAR